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doi:10.1016/j.jtcvs.2003.11.0161366 The Journal of Thoracic and CardBackground: We sought to determine the cost-effectiveness of different treatment
strategies for patients with pulmonary metastases from soft tissue sarcoma.
Methods: We constructed a decision tree to model the outcomes of 4 treatment
strategies for patients with pulmonary metastases from soft tissue sarcoma: pulmo-
nary resection, systemic chemotherapy, pulmonary resection and systemic chemo-
therapy, and no treatment. Data from 1124 patients with pulmonary metastases from
soft tissue sarcoma were used to estimate disease-specific survival for pulmonary
resection and no treatment. Outcomes of systemic chemotherapy and pulmonary
resection and of systemic chemotherapy were estimated by assuming a 12-month
improvement in disease-specific survival with chemotherapy; this was done on the
basis of the widely held but unproven assumption that chemotherapy provides a
survival benefit in patients with metastatic soft tissue sarcoma. Direct costs were
examined for a series of patients who underwent protocol-based pulmonary resec-
tion or doxorubicin/ifosfamide-based chemotherapy.
Results: The mean cost of pulmonary resection was $20,339 per patient; the mean
cost of 6 cycles of chemotherapy was $99,033. Compared with no treatment and
assuming a 12-month survival advantage with chemotherapy, the incremental cost-
effectiveness ratio was $14,357 per life-year gained for pulmonary resection,
$104,210 per life-year gained for systemic chemotherapy, and $51,159 per life-year
gained for pulmonary resection and systemic chemotherapy. Compared with pul-
monary resection, the incremental cost-effectiveness ratio of pulmonary resection
and systemic chemotherapy was $108,036 per life-year gained. Sensitivity analyses
showed that certain patient and tumor features, as well as the assumed benefit of
chemotherapy, affected cost-effectiveness.
Conclusions: For patients with pulmonary metastases from soft tissue sarcoma who
were surgical candidates, pulmonary resection was the most cost-effective treatment
strategy evaluated. Even with favorable assumptions regarding its clinical benefit,
systemic chemotherapy alone, compared with no treatment, was not a cost-effective
treatment strategy for these patients.
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TSApproximately 8300 new cases of soft tis-sue sarcoma (STS) are diagnosed annu-ally in the United States, and fewer than50% of patients with this diagnosis willreceive curative treatment with currenttreatment modalities.1 The lungs are the
most common site of metastatic disease; pulmonary metas-
tases affect 20% to 38% of all STS patients.2-4 Indeed, most
patients who die of STS will have pulmonary metastases.
Several studies have demonstrated that a subgroup of
patients with isolated, resectable pulmonary metastases
from STS may be cured by pulmonary metastasectomy.3-11
These studies show pulmonary resection (PR) to be associ-
ated with low perioperative mortality rates, actuarial 3-year
survival of 20% to 54%, and 5-year survival of 21% to 51%.
However, some of these studies are limited by median
follow-up durations of less than 3 years.6,7 Nevertheless, PR,
when possible, has been advocated as the only potentially
curative treatment in STS patients with lung metastases.12
Anthracycline-based chemotherapy is commonly used in
patients with metastatic STS,13,14 although there has never
been a randomized clinical trial comparing systemic che-
motherapy with best supportive care in this group of pa-
tients. The combination of systemic chemotherapy and re-
section of STS pulmonary metastases is also commonly
used.15-17 This approach is believed by some physicians to
allow for more complete treatment of both macroscopic and
occult microscopic metastatic disease. Unfortunately, a ran-
domized trial designed to evaluate the potential clinical
benefit of metastasectomy plus chemotherapy (European
Organization for Research and Treatment of Cancer trial
62933) closed because of poor accrual. As a consequence,
there is no consensus on the optimal therapeutic approach
for patients with pulmonary metastases from STS.
In the absence of definitive clinical trials to guide treat-
ment decisions, other considerations enter into decision-
making for patients with metastatic STS. These consider-
ations include the natural history of the disease, toxicities of
currently available treatments, and, increasingly, issues of
cost-effectiveness. The objective of this study was to exam-
ine the cost-effectiveness of different treatment options for
patients with pulmonary metastases from STS.
Patients and Methods
Decision Analysis
Using a decision-analytic approach,18,19 we modeled the outcomes
of 4 strategies for the treatment of STS pulmonary metastases: PR,
systemic chemotherapy, PR and systemic chemotherapy (PRC),
and no treatment (NoRx). Consistent with the methodology of
decision analysis, we estimated the expected costs and expected
outcomes for each strategy. A summary of this model is depicted
in Figure 1.
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Median disease-specific survival was used as the primary outcome
measure. This was estimated for the PR and NoRx groups on the
basis of an updated outcome analysis of 1124 consecutive patients
with STS pulmonary metastases treated and followed up at Me-
morial Sloan-Kettering Cancer Center. Data from the 235 patients
within this cohort who underwent complete resection of all pul-
monary metastases were used to estimate the outcome for PR; data
from the remaining 889 patients were used to estimate the outcome
for NoRx. This single-institution series represents a prospective
cohort of patients with STS pulmonary metastases.4 The treatment
groups (PR or NoRx) were not randomized in this cohort, thus
creating potential patient- and disease-related biases. However, as
a consecutive series (1982-1997), these data are believed to be the
most comprehensive currently available outcome data for patients
with STS pulmonary metastases. Sensitivity analyses were per-
formed to examine the effect of any imprecision in the outcomes
estimated for these 2 groups.
Outcomes of systemic chemotherapy and PRC were esti-
mated by generously assuming a 12-month improvement in dis-
ease-specific survival with chemotherapy in the base case (NoRx
and PR, respectively). This was done on the basis of the widely
held but unproven assumption that chemotherapy provides a sur-
vival benefit in patients with metastatic STS. All survival out-
comes were discounted at a rate of 3% per annum and were
calculated on a yearly basis.
Costs
Costs—not charges—were used in all economic analyses. Total
costs were calculated as the sum of fixed and variable direct costs.
Variable costs, which represent costs that are saved if a given
procedure is not performed (eg, the cost of a radiologist’s inter-
preting a chest computed tomography study), were determined
with the aid of specialized computer software (Hospital Cost
Consultants, Chicago, IL) and relied on information from a general
ledger. Included in these variable costs were professional costs
incurred by the hospital. Fixed costs, which represent costs that are
incurred even if a procedure is not performed (eg, the overhead
costs associated with a computed tomography scanner), were ob-
tained by means of a statistical allocation from The University of
Texas M. D. Anderson Cancer Center’s cost accounting software.
Total costs did not include any measurement or estimation of costs
of patient time, non–health-care costs (eg, baby-sitting or trans-
portation), or lost wages. All cost data were indexed to 2001 US
dollars by multiplying recorded costs by the percentage inflation-
ary increase, based on the medical component of the consumer
price index, for each fiscal year in a compound manner.
Costs of chemotherapy were obtained from a cohort of 26
patients with metastatic STS who received contemporary STS
chemotherapy consisting of doxorubicin (75 mg/m2 per cycle) and
ifosfamide (10 g/m2 per cycle). Chemotherapy was provided in the
context of a standardized treatment protocol at The University of
Texas M. D. Anderson Cancer Center. Patients received a median
of 4 cycles (range, 2-7) of chemotherapy. We included costs
associated with in-hospital and outpatient care from the first day of
chemotherapy to 30 days after completion of the last cycle. The
mean cost per cycle of chemotherapy was calculated, and we then
and Cardiovascular Surgery ● Volume 127, Number 5 1367
General Thoracic Surgery Porter et al
G
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systemic chemotherapy and PRC base model.
Costs associated with surgery were obtained from a consecu-
tive series of 46 patients who underwent resection of STS pulmo-
nary metastases at M. D. Anderson Cancer Center. Pulmonary
metastasectomy was performed according to an institutional clin-
ical pathway protocol. Operative approaches included posterolat-
eral thoracotomy, median sternotomy, clamshell (bilateral antero-
lateral) thoracotomy, and staged bilateral posterolateral
thoracotomies. Additional resectable pulmonary metastases devel-
oped in 6 patients within 1 year of initial PR and were treated with
repeat resection. Costs included the preoperative consultations, all
inpatient care, and all outpatient care up to 30 days after discharge.
Costs of repeat and staged resections were added to the costs of the
original operation for each patient thus treated. All surgery costs
were expressed on a per-patient basis.
For this study, we assumed that the costs of NoRx were the
baseline costs of supportive care and were applicable to all 4
groups; therefore, these costs were not estimated or calculated. The
costs of PRC were calculated by simply adding the costs calcu-
lated for PR alone and systemic chemotherapy alone. Because all
examined costs occurred within the first year, no cost discounting
was performed.
The measure of cost-effectiveness was the incremental cost-
effectiveness ratio (ICER), which is the difference in the costs of
Figure 1. Decision tree. Summary of the analytic mo
patients with soft tissue sarcoma pulmonary metastase
pulmonary resection alone, systemic chemotherapy al
Summary costs and outcomes (prior to discounting) ar2 strategies divided by the difference in survival with the 2
1368 The Journal of Thoracic and Cardiovascular Surgery ● Mastrategies. Otherwise stated, the ICER expressed the additional
cost per life-year gained of one treatment strategy versus another.
The ICER is a widely used, standard measure of cost-effective-
ness.20,21 In this study, the ICER was calculated as follows:
ICER Cx  Cy/Sx  Sy]/12,
where Cx is the cost per patient of treatment strategy x, CY is the
cost per patient of treatment strategy y, Sx is the survival (in
months) with treatment strategy x, and Sy is the survival (in
months) with treatment strategy y.
Because no appropriate published data exist that quantify the
survival benefit associated with chemotherapy in STS patients with
pulmonary metastases, we performed a 1-way sensitivity analysis
by altering the assumed benefit of chemotherapy in the systemic
chemotherapy and PRC groups. Sensitivity analyses were also
performed for specific patient subgroups (by age, grade, anatomic
site, and disease-free interval) with the assumption that costs did
not differ across these subgroups but that outcomes did. We also
examined the effect on the ICER of delivering 4 cycles of chemo-
therapy instead of 6.
Results
Costs and survival of the 4 strategies, in the base case model
and before discounting, are presented in Figure 1. The mean
omparing 4 hypothetical management strategies for
e algorithm models possible outcomes of no treatment,
and pulmonary resection and systemic chemotherapy.
luded at the right of the figure. pt, Patient.del c
s. Th
one,
e inccost of PR was $20,339 (SEM, $2718); the mean cost of
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TSsystemic chemotherapy (6 cycles) was $99,033 (SEM,
$9855). Compared with NoRx and assuming a 12-month
survival advantage with chemotherapy, the ICER was
$14,357 per life-year gained for PR, $104,210 per life-year
gained for systemic chemotherapy, and $51,159 per life-
year gained for PRC. Compared with PR, the ICER of
PRC was $108,036 per life-year gained.
Results of altering the assumed benefit of chemotherapy
are displayed graphically in Figure 2. The ICER of PR
remained smaller than that for PRC, even for extremes of
chemotherapy benefit (36-month survival benefit).
The outcomes and resultant ICERs for specific patient
subgroups treated with PR and PRC compared with NoRx
are shown in Table 1. The result of systemic chemotherapy
alone is not shown in this table because this strategy was
dominated (both less effective and more costly) throughout
all patient subgroups. The ICER for both PR and PRC
Figure 2. A, Incremental cost-effectiveness ratio (ICER)
and pulmonary resection with chemotherapy (PRC),
benefits assuming administration of 6 cycles of chemot
with no treatment, for varying chemotherapy benefits
Systemic chemotherapy.seemed to be quite sensitive to the tumor site and disease-
The Journal of Thoracicfree interval: substantial increases in ICER were noted in
patients with extremity tumors and those with a disease-free
interval of less than 12 months from treatment of their
primary tumor.
The effect of postresection survival on the decision-
analysis model was examined in a 1-way sensitivity analysis
by using literature-based estimates of median overall sur-
vival after PR.3-9,11 The relationship between postmetasta-
sectomy survival and the ICER for PR and PRC, holding
costs constant, is depicted in Figure 3.
We repeated analyses under the assumption that 4 (not 6)
cycles of systemic chemotherapy would be necessary for a
given survival benefit. With the baseline model of a 12-
month survival benefit attributable to chemotherapy, the use
of 4 cycles of chemotherapy resulted in an ICER of $69,497
per life-year gained for systemic chemotherapy and $37,012
per life-year gained for PRC (ICER for PR was un-
emotherapy alone (C), pulmonary resection alone (PR),
pared with no treatments, for varying chemotherapy
py. B, ICER of C alone, PR alone, and PRC, compared
ming administration of 4 cycles of chemotherapy. C,of ch
com
hera
assuchanged at $14,357 per life-year gained; Figure 2).
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PRC, compared with NoRx, was highly sensitive to
changes in the assumed benefit of chemotherapy, we calcu-
lated the minimum chemotherapy benefit necessary to ob-
tain an ICER below the conventionally accepted threshold
of $50,000 per life-year gained. With 6 cycles of chemo-
therapy, a greater than or equal to 32-month survival benefit
must be obtained with chemotherapy to reach this threshold
for systemic chemotherapy, whereas a greater than or equal
to 14-month benefit must be achieved with chemotherapy
for PRC. If only 4 cycles of chemotherapy are modeled,
the required benefit of chemotherapy decreases to greater
than or equal to 17 months and greater than or equal to 4
months for systemic chemotherapy and PRC, respec-
tively.
Discussion
The management of localized STS has improved over the
past 25 years. For patients with extremity STS, there has
been a migration from amputation to conservative surgery
and radiotherapy as the primary form of local therapy.
However, although amputation rates have declined,22 there
has been no decrease in sarcoma-related mortality rates.23-25
Unfortunately, distant metastases remain a common pattern
of treatment failure,2,26 and although adjuvant chemother-
apy has been used to reduce this risk, its efficacy is modest
at best.27 Thus, the optimal management of pulmonary
metastases is a major issue for physicians treating patients
with STS.
No randomized clinical trials have been performed ex-
TABLE 1. Outcomes and resultant ICERs for PR and PRC
Subgroup
NoRx
survival*
(mo)
Sur
(
All patients 13
Age (y)
50 y 16
50 y 12
Tumor grade
Low 21
High 13
Tumor site
Extremity/trunk 12
Retroperitoneum 12
Visceral 17
Disease-free interval (mo)
12 10
12 16
NoRx, No treatment; PR, pulmonary resection; PRC, pulmonary resectio
life-year gained.
*Before discounting.
†Compared with NoRx.amining whether there is a benefit to doxorubicin-based
1370 The Journal of Thoracic and Cardiovascular Surgery ● Machemotherapy versus best supportive care in the treatment
of patients with metastatic STS. Similarly, no clinical trials
have examined whether such chemotherapy, when com-
bined with PR, offers a survival advantage compared with
operation alone. However, a cost-effectiveness analysis
such as ours is dependent on a quantified survival advantage
to chemotherapy; if no advantage existed, the examination
of the cost-effectiveness of chemotherapy, either alone or
combined with PR, would be without basis. The 12-month
survival advantage with doxorubicin-based chemotherapy
assumed in our base model is empiric and quite possibly
represents an overestimation of the benefit of chemother-
apy. Furthermore, the sensitivity analysis performed by
altering the survival benefit of chemotherapy showed that a
survival benefit of at least 32 months was required before
the ICER with the chemotherapy-alone strategy decreased
below the arbitrary, but conventionally accepted as cost-
effective, threshold of $50,000 per life-year gained. The
ability of any currently available chemotherapy regimen to
provide such a survival advantage is not supported by any
evidence, either direct or indirect.
In interpreting the aggregate data reported in this study,
it is important to recognize the relative strengths and limi-
tations of our methodology. This study used cost data (the
amount of money required to actually provide a medical
service) and not charge data (the amount of money a patient
or third-party payer is asked to pay for a given medical
service). Although charge data are generally easier to ob-
tain, the use of cost data is less prone to the potential biases
of different payer profit margins. Moreover, costs are less
pared with NoRx
PR PRC
ICER†
($/LYG)
Survival*
(mo)
ICER†
($/LYG)
14,357 43 51,159
17,310 43 57,070
13,559 43 49,395
9841 60 40,570
18,351 39 58,949
23,245 35 66,012
6041 68 28,254
6856 68 31,277
36,428 29 79,142
9724 55 40,125
systemic chemotherapy; ICER, incremental cost-effectiveness ratio; LYG,com
vival*
mo)
31
31
31
48
27
23
56
56
17
43
n andprone to the large variations in charges seen between dif-
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TSferent institutions. Because costs theoretically do not in-
clude profits and deficits incurred by hospitals and third-
party payers to provide a medical service, they are believed
to be more reflective of the patient, physician, and societal
perspectives.28 Costs used in this study (M. D. Anderson
Cancer Center) may vary in other regions of the country;
however, relative differences should be similar.
A potential limitation of this study is that cost and
outcome estimates were not obtained from the same cohort
of patients. This study took advantage of long-term outcome
data from a large cohort of consecutively treated patients
with STS pulmonary metastases and the only available cost
data for patients with metastatic STS undergoing systemic
doxorubicin-based chemotherapy or PR. The availability of
cost data (rather than charges) was a consequence of spe-
cific cost accounting systems in place at the M. D. Anderson
Cancer Center; such data were not available at Memorial
Sloan-Kettering Cancer Center at the time of the study. In
our opinion, the difficulties in using either of these patient
cohorts for both cost and outcome data were far greater than
the methodologic limitations of using different patient co-
horts for cost and outcome data, especially because subse-
quent sensitivity analyses could be performed to specifically
address the effects of cost and outcome variations.
Some of the 889 patients seen at Memorial Sloan-Ket-
tering Cancer Center who did not undergo complete surgical
resection of pulmonary metastases and were used to esti-
mate the outcome of NoRx actually did receive chemother-
apy at some point in their clinical course. However, because
of the heterogeneity of this chemotherapy, we decided to
consider them in aggregate as having received no therapy
and to assign hypothetical additive benefits of chemother-
apy to estimate the outcome of systemic chemotherapy.
This decision may have falsely inflated the outcome of
NoRx. However, such an effect would imply that the ICERs
of PR reported in this study were in fact overestimates and
that PR is in fact more beneficial, in terms of cost-effec-
tiveness, than the results of this study describe.
This was a study of cost-effectiveness and not a cost-
utility study. Otherwise stated, the units of outcome used
(life-years gained) were not weighted and thus reflect only
differences in survival time—not potential differences in
quality of life. One could hypothesize that surgical strate-
gies would be associated with more up-front quality of life
effects, whereas the effect of systemic chemotherapy might
be observed over a longer time interval, as found for other
malignancies.29-31 However, the retrospective nature of this
analysis did not permit assessment of temporal differences
in quality of life among the different treatment strategies.
Given the marked cost differences between PR and systemic
chemotherapy, future prospective research in this area
should include evaluation of quality-of-life parameters.
The Journal of ThoracicThis study did not estimate the baseline costs of support-
ive care. Thus, even though it may be reasonable to assume
that the absolute costs associated with supportive care were
the same for each treatment strategy, we did not account for
the discounting of these costs. Discounting effectively as-
signs a lower value, based on an annual percentage, to costs
that occur in the future compared with present-day costs.
However, discounting these costs would result in lower
ICERs for treatment strategies with longer survival; the lack
of discounting supportive care costs therefore biased the
results against PR and PRC. Thus, even if we explicitly
included the discounting of supportive care, it would make
the strategies that included PR even more favorable from an
economic perspective.
The results of this study can be applied only to patients
with STS pulmonary metastases who could potentially be
treated by any of the 4 outlined treatment options; decision
analysis requires that a decision about treatment options can
be made. Thus, we cannot extrapolate the study findings to
a patient population that is ineligible for 1 or more or the 4
treatment strategies. Specifically, this study does not di-
rectly evaluate the cost-effectiveness of systemic chemo-
therapy in patients with STS pulmonary metastases who are
not candidates for complete pulmonary metastasectomy.
Such patients may represent a significant proportion of STS
patients with pulmonary metastases.
Similarly, the results of this study apply to the therapeu-
tic approaches used; significant differences in surgical or
chemotherapy treatment approaches may affect cost-effec-
tiveness. For example, the use of video-assisted thoraco-
scopic surgery as the surgical approach to metastasectomy
Figure 3. Effect of post-resection survival on the incremental
cost-effectiveness ratio (ICER), based on literature estimates of
survival, for pulmonary resection alone (PR) and PR plus chemo-
therapy (PRC) compared with no treatment. Solid stars indicate
the survival estimated used in this study.may decrease the costs associated with the operation but
and Cardiovascular Surgery ● Volume 127, Number 5 1371
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surgery used in this study.32,33
The results of this study provide cost-effectiveness data
to support the existing therapeutic principle that when pos-
sible, pulmonary metastases should be resected. Whether
the combination of resection with systemic chemotherapy is
warranted, on the basis of cost-effectiveness and published
outcome data, is less clear. It was not until a survival benefit
attributable to systemic chemotherapy greater than or equal
to 14 months was assumed that the ICER of PRC, com-
pared with NoRx, decreased below the threshold of $50,000
per life-year saved. However, compared with PR alone, the
ICER of adding systemic chemotherapy required a chemo-
therapy survival benefit of 33 months before this threshold
was reached.
In summary, this study found that, for patients with STS
pulmonary metastases, PR was the most cost-effective treat-
ment strategy evaluated; chemotherapy alone in patients
with resectable STS pulmonary metastases was not a cost-
effective treatment strategy. Certain patient and tumor fea-
tures, such as low tumor grade, nonextremity tumor loca-
tion, and a disease-free interval greater than or equal to 12
months, were associated with a greater cost-effectiveness of
treatment. Notwithstanding the generous assumptions about
the clinical benefit of chemotherapy used in these analyses,
the incremental cost-effectiveness of adding chemotherapy
to PR was uncertain. It is to be hoped that randomized trials
can be developed to better address the potential clinical
benefit, cost-effectiveness, and quality of life associated
with different treatment strategies for patients with meta-
static STS.
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